<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01227356</url>
  </required_header>
  <id_info>
    <org_study_id>NordCML002</org_study_id>
    <nct_id>NCT01227356</nct_id>
  </id_info>
  <brief_title>A Study Comparing Imatinib and Imatinib/Pegylated Interferon in Chronic Myeloid Leukemia</brief_title>
  <official_title>A Randomized Study Comparing Imatinib And Imatinib/Pegylated Interferon Alpha-2B in Newly Diagnosed Non-high Risk Chronic Myeloid Leukemia Patients in Complete Hematological Remission After Imatinib Induction Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Uppsala University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Uppsala University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Uppsala University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with chronic myeloid leukemia in imatinib induced CHR are randomized between
      imatinib 400 mg daily and imatinib 400 mg daily + PegIntron 30 ug weekly.

      Primary endpoint: To compare at 12 months between the treatment arms the rate of Major
      Molecular Response (=99,9% tumour reduction) at 12 months
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      130 patients registered, 112 randomized. 56 pats in each treatment arm. 12 months study
      duration. Rate of Major Molecular Response was at 12 months 53 vs 82 % (p=0.002) in favour of
      the combination arm.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of rate Major Molecular Response between treatment arms</measure>
    <time_frame>2004 - 2009</time_frame>
    <description>Molecular response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of complete cytogenetic response between the treatment arms at 12 months</measure>
    <time_frame>2004 - 2009</time_frame>
    <description>Cytogenetic response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison rate complete cytogenetic response between the treatment arms at 12 months</measure>
    <time_frame>2004 - 2009</time_frame>
    <description>Hematologic response</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">112</enrollment>
  <condition>Health Care Quality</condition>
  <condition>Health Care Evaluation</condition>
  <arm_group>
    <arm_group_label>imatinb + pegIntron</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>imatinib and pegylated interferon</intervention_name>
    <description>imatinib 400 mg p.o. daily pegylated interferon 50 ug s.c. weekly</description>
    <arm_group_label>imatinb + pegIntron</arm_group_label>
    <other_name>Gleevec</other_name>
    <other_name>PegIntron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Chronic myeloid leukemia in imatinib induced complete hematological remission.
        Intermediate/low risk, ECOG &lt; 2

        Exclusion Criteria:

        Les than CHR after 3 months imatinib high risk More than 6 months from diagnosis ECOG &gt; 2
        Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>bengt NO Simonsson, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Uppsala</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bengt Simonsson</name>
      <address>
        <city>Uppsala</city>
        <zip>S-75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uppsala University Hospital</name>
      <address>
        <city>Uppsala</city>
        <zip>S-753 20</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uppsala University Hospital</name>
      <address>
        <city>Uppsala</city>
        <zip>S-75320</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2010</study_first_submitted>
  <study_first_submitted_qc>October 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2010</study_first_posted>
  <last_update_submitted>October 22, 2010</last_update_submitted>
  <last_update_submitted_qc>October 22, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2010</last_update_posted>
  <responsible_party>
    <name_title>Bengt Simonsson/Professor</name_title>
    <organization>Uppsala University</organization>
  </responsible_party>
  <keyword>Chronic myeloid leukemia, imatinib, interferon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Imatinib Mesylate</mesh_term>
    <mesh_term>Peginterferon alfa-2b</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

